Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

Jeremiah Stamler, Olga Vaccaro, James D. Neaton et al. · Diabetes Care · 1993 · 4.1K citations

Medicine, Chronic Disease Prevention, Internal Medicine +14

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald et al. · New England Journal of Medicine · 2013 · 3.5K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Philip Home, Stuart Pocock, Henning Beck‐Nielsen et al. · The Lancet · 2009 · 1.4K citations

Medicine, Pharmacology, Pharmacotherapy +17